Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

计划入组 21 人 · 首次发布于 2022 年 7 月 22 日

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

计划入组 208 人 · 首次发布于 2023 年 9 月 29 日

Prospective, Comparative Assessment of Alveolar Bone Augmentation Using GUIDOR® Membrane in the Bound Edentulous Space

计划入组 6 人 · 首次发布于 2015 年 3 月 12 日

NKX101

Deep-IL15

Hu14.18-IL15

Telix Pharmaceuticals

Australia

MiMedx

United States

Comstock Metals Ltd

Australia

Obsidian and Galera Therapeutics Announce $350 Million Merger to Advance Next-Generation TIL Cell Therapy

Obsidian Therapeutics Enrolls First Patient in Registration-Enabling Cohort for Amsoki-cel TIL Therapy in Advanced Melanoma

Advancements in PSMA-Targeted Radionuclide Therapy for Metastatic Prostate Cancer